Institut Claudius Regaud; Departement Oncologie Medicale

Toulouse 31059

0 studies enrolling now · 16 studies all time

What they study most

Advanced Solid Tumors, Advanced/Metastatic Tumors, Bladder Cancer, Breast Cancer, Cancer of Head and Neck, Carcinoma, Transitional Cell, Colorectal Cancer, Hematologic Malignancies, Multiple Myeloma, Neoplasms, Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute, Neoplasms, Prostatic Neoplasms, Castration-Resistant

Studies at this site

• Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors — Completed
• A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen — Completed
• A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) — Completed
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) — Stopped early
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection — Stopped early
• Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) — Completed
• A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) — Completed
• A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer — Completed
• A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors — Completed
• A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] — Completed
• A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors — Completed
• A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors — Completed
• A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors — Completed
• A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers — Completed
• An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies — Completed
• Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer — Completed